Chapter 1

Hearing's Fallen Leader

Figures converted from CHF at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Sonova is the world's largest maker of hearing aids — a Swiss blue-chip that compounded into a share price near $434 in late 2021 and now trades at roughly half that. Sales have stalled around $4.5 billion, operating margins have fallen from 22.6% to 18.7%, and a four-year push into consumer audio is being unwound at a loss. The balance sheet is a fortress; the growth story is on trial.

What Sonova is

Sonova Holding AG designs, makes and sells hearing solutions under four brands — Phonak and Unitron (prescription hearing aids), Advanced Bionics (cochlear implants), and, until recently, Sennheiser-branded consumer audio (under license) [1]. It runs both sides of the value chain: it manufactures the devices and operates one of the world's largest retail networks of hearing-care stores (AudioNova and other banners) that fit them [2]. The company was founded as Phonak in 1947, has traded on the SIX Swiss Exchange since 1994, and is a constituent of the blue-chip SMI index.

The business reports in two segments. Hearing Instruments — the prescription wholesale devices plus the retail store network — is the engine, at $4,194.4 million of external sales in fiscal 2025/26 [3]. Cochlear Implants — surgically implanted devices for severe-to-profound loss — is the small, higher-tech second leg at $315.3 million, and it is currently shrinking [4]. The company's fiscal year ends 31 March; "FY2026" here means the year ended 31 March 2026.

Sources: share price and drawdown from market data as reported (peak of approximately $434 on 5 November 2021); sales and EPS from FY2025/26 consolidated income statement [5].

At $257 the company is worth roughly $15.3 billion — a mid-to-large-cap by Swiss standards, and no longer the premium-rated compounder it was four years ago.

Why the market fell out of love

The demand backdrop is one of the most durable in healthcare. About 1.5 billion people — a fifth of the world's population — live with some degree of hearing loss, and roughly 430 million have moderate-or-worse loss, a number that rises as populations age; most of them go untreated [6]. A leader in a low-penetration, demographically tailwinded market is exactly the kind of franchise that earns a premium multiple — which is what Sonova had, until it didn't.

Four things turned the story. Growth normalized after a post-pandemic surge (sales grew 29% in FY2022, then went sideways). Margins compressed. A diversification bet failed. And a technology fear arrived.

Source: FY2025/26 Annual Report, Five Year Key Figures — restated to continuing operations; converted from CHF at each year's 31 March rate [7].

Revenue has been essentially flat for four years in local currency while operating profit has drifted lower (the dollar series is lifted by a stronger franc). The clearer signal is the margin: EBIT margin fell from 22.6% in FY2022 to 18.7% in FY2026, a step-down of nearly four points that has never fully recovered.

Source: FY2025/26 Annual Report, Five Year Key Figures [8].

Gross margin has actually held above 73%, so the erosion is below the gross line — in operating cost, particularly sales-and-marketing intensity that climbed as growth slowed. Whether that compression is cyclical or structural is one of the report's central threads.

The Sennheiser round-trip

In March 2022 Sonova bought Sennheiser's consumer audio division to push into "hearables" and reach consumers earlier in their hearing journey — a hedge against the fear that consumer electronics would encroach on hearing care [9]. Four years later, on 23 March 2026, management announced it would sell the business back out, booking a $47.9 million pre-tax impairment and classifying Consumer Hearing as discontinued operations [10]. The unit lost $133.2 million after tax in FY2026, which is why reported earnings per share fell to $9.03 even as continuing operations earned $11.28 [11].

The technology fear it was meant to answer became concrete in September 2024, when U.S. regulators cleared software turning Apple's AirPods Pro into an over-the-counter hearing aid. Hearing-aid stocks slid on the news; sell-side analysts argued the OTC market targets a different, milder-loss population than Sonova's prescription base. The debate over whether Apple and OTC devices commoditize the core franchise — or merely widen the funnel into it — is unresolved and belongs to a later chapter.

A fortress balance sheet, and no founder

For an investor who wants the probability of ruin near zero, Sonova is reassuring. Net debt was $1,243.5 million at 31 March 2026 — roughly 1.2 times normalized operating profit before amortization — and it has fallen every year since FY2023 in local currency [12]. The dividend was raised through the entire de-rating, from CHF 4.40 to a proposed CHF 4.70 per share ($4.76 to $5.88 at each year's rate) [13]. Bankruptcy is not the risk here.

Source: FY2025/26 Annual Report, Five Year Key Figures — restated to continuing operations; converted from CHF at each year's 31 March rate [14].

What Sonova is not is founder-run. Its board is entirely non-executive and independent, with no controlling shareholder [15], and the company changed both its chief executive — Arnd Kaldowski to Eric Bernard, who took over in September 2025 — and its chairman during 2025 [16]. Skin in the game runs low: this is professionally managed, widely held Swiss equity, not an owner-operator with a large personal stake. For an investor who prizes aligned insiders, that is a genuine gap in the fit — one that management compensation and ownership deserve their own examination.

What management now promises, and what the market pays for it

Alongside the divestment, management set a fresh ambition: CHF 6 billion (about $7.5 billion) of revenue by FY2030/31, up from $4.5 billion today, built on a re-focused hearing-care portfolio [17]. Consensus is more restrained but still points up: analysts model earnings per share recovering to roughly $13.0 in FY2026/27 and $14.3 in FY2027/28 (CHF 10.4 and CHF 11.4), back above the FY2023 peak. At $257, the shares change hands near 20 times that forward number and yield about 2.2% — cheaper than the 30-plus multiple of the boom years, but not the deep-value price of a broken business.

That framing sets up the question this report is built to answer.

Everything that follows tests one side of that question or the other: whether the margin step-down reverses, whether the moat holds against OTC and Apple, whether capital allocation and incentives are trustworthy, and what a demanding margin of safety would require the price to be.